Amgen Wins Appeals Court Ruling Upholding Patents on Enbrel

Bookmark
(Bloomberg) -- Amgen Inc. won an appeals court ruling that would block a biosimilar of its top-selling rheumatoid arthritis drug Enbrel by Novartis AG’s Sandoz until 2029.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.